From the Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Nuclear Medicine, Peking University Cancer Hospital & Institute, Beijing, China.
Clin Nucl Med. 2021 Nov 1;46(11):e534-e537. doi: 10.1097/RLU.0000000000003598.
A 52-year-old man complained of pain in the right lower chest wall for a month. Chest CT found a subpleural mass, but failed to identify the nature of the tumor. The 18F-FDG PET/CT was conducted for further diagnosis and staging, which showed the mass in the lower lobe of the right lung with mild radioactive uptake of 18F-FDG. The patient was subsequently enrolled in an ongoing clinical trial using 68Ga-DOTA-FAPI-04 (fibroblast activation protein inhibitor) PET/CT. The mass showed intensive 68Ga-DOTA-FAPI-04 uptake, which was subsequently confirmed as solitary fibrous tumors of the pleura by pathology. Our case demonstrated that the 68Ga-DOTA-FAPI-04 might have excellent tumor affinity of solitary fibrous tumors of the pleura.
一位 52 岁男性因右胸下部壁疼痛持续一个月就诊。胸部 CT 发现一胸膜下肿块，但未能确定肿瘤性质。为进一步诊断和分期行 18F-FDG PET/CT 检查，结果显示右肺下叶肿块伴 18F-FDG 轻度摄取。随后该患者入组一项正在进行的临床研究，采用 68Ga-DOTA-FAPI-04（成纤维细胞激活蛋白抑制剂）PET/CT。肿块显示强烈的 68Ga-DOTA-FAPI-04 摄取，随后病理证实为胸膜孤立性纤维瘤。本病例表明，68Ga-DOTA-FAPI-04 可能对胸膜孤立性纤维瘤具有优异的肿瘤亲和力。
